Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, CH-4058, Basel, Switzerland.
Department of Biosystems Science and Engineering, ETH Zurich, Mattenstrasse 26, CH-4058, Basel, Switzerland; University of Basel, Faculty of Science, Mattenstrasse 26, CH-4058, Basel, Switzerland.
Curr Opin Biotechnol. 2019 Aug;58:108-116. doi: 10.1016/j.copbio.2019.02.023. Epub 2019 Mar 30.
Mammalian synthetic biology has evolved to become a key driver of biomedical innovation in the area of cell therapy. Advances in receptor engineering, immunotherapy and cell implants promise new treatment options for complex diseases. Synthetic receptors have already found applications in cellular immunotherapy for cancer treatment, and are being introduced into the field of cell implants. Here, we discuss prospects for the next generation of engineered mammalian cells for human therapy, highlighting selected recent studies.
哺乳动物合成生物学已经发展成为细胞治疗领域生物医学创新的关键驱动力。受体工程、免疫疗法和细胞植入物方面的进展为复杂疾病提供了新的治疗选择。合成受体已经在癌症治疗的细胞免疫疗法中得到应用，并正在被引入细胞植入物领域。在这里，我们讨论了下一代用于人类治疗的工程化哺乳动物细胞的前景，重点介绍了最近的一些研究。
